169 related articles for article (PubMed ID: 26727970)
1. A therapeutic cancer vaccine against GL261 murine glioma.
Kindy MS; Yu J; Zhu H; Smith MT; Gattoni-Celli S
J Transl Med; 2016 Jan; 14():1. PubMed ID: 26727970
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Immune Responsiveness to Glioma by Vaccination of Mice with Established Brain Gliomas with a Semi-Allogeneic Vaccine.
Gattoni-Celli S; Young MR
Int J Mol Sci; 2016 Sep; 17(9):. PubMed ID: 27598146
[TBL] [Abstract][Full Text] [Related]
3. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas.
Newcomb EW; Demaria S; Lukyanov Y; Shao Y; Schnee T; Kawashima N; Lan L; Dewyngaert JK; Zagzag D; McBride WH; Formenti SC
Clin Cancer Res; 2006 Aug; 12(15):4730-7. PubMed ID: 16899624
[TBL] [Abstract][Full Text] [Related]
4. Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.
Clark AJ; Safaee M; Oh T; Ivan ME; Parimi V; Hashizume R; Ozawa T; James CD; Bloch O; Parsa AT
J Transl Med; 2014 Dec; 12():345. PubMed ID: 25464980
[TBL] [Abstract][Full Text] [Related]
5. Vaccination for experimental gliomas using GM-CSF-transduced glioma cells.
Herrlinger U; Kramm CM; Johnston KM; Louis DN; Finkelstein D; Reznikoff G; Dranoff G; Breakefield XO; Yu JS
Cancer Gene Ther; 1997; 4(6):345-52. PubMed ID: 9408604
[TBL] [Abstract][Full Text] [Related]
6. Convection-enhanced delivery of temozolomide and whole cell tumor immunizations in GL261 and KR158 experimental mouse gliomas.
Enríquez Pérez J; Kopecky J; Visse E; Darabi A; Siesjö P
BMC Cancer; 2020 Jan; 20(1):7. PubMed ID: 31900109
[TBL] [Abstract][Full Text] [Related]
7. Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
Hunn MK; Farrand KJ; Broadley KW; Weinkove R; Ferguson P; Miller RJ; Field CS; Petersen T; McConnell MJ; Hermans IF
Clin Cancer Res; 2012 Dec; 18(23):6446-59. PubMed ID: 23147997
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic vaccination against malignant gliomas based on allorecognition and syngeneic tumor antigens: proof of principle in two strains of rat.
Stathopoulos A; Samuelson C; Milbouw G; Hermanne JP; Schijns VE; Chen TC
Vaccine; 2008 Mar; 26(14):1764-72. PubMed ID: 18336964
[TBL] [Abstract][Full Text] [Related]
9. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.
Kjaergaard J; Wang LX; Kuriyama H; Shu S; Plautz GE
J Neurosurg; 2005 Jul; 103(1):156-64. PubMed ID: 16121986
[TBL] [Abstract][Full Text] [Related]
10. Glioma-specific cytotoxic T cells can be effectively induced by subcutaneous vaccination of irradiated wild-type tumor cells without artificial cytokine production.
Iwadate Y; Yamaura A; Sakiyama S; Sato Y; Tagawa M
Int J Oncol; 2003 Aug; 23(2):483-8. PubMed ID: 12851699
[TBL] [Abstract][Full Text] [Related]
11. Implantation of GL261 neurospheres into C57/BL6 mice: a more reliable syngeneic graft model for research on glioma-initiating cells.
Yi L; Zhou C; Wang B; Chen T; Xu M; Xu L; Feng H
Int J Oncol; 2013 Aug; 43(2):477-84. PubMed ID: 23708048
[TBL] [Abstract][Full Text] [Related]
12. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-gamma thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts.
Spagnolo A; Glick RP; Lin H; Cohen EP; Feinstein DL; Lichtor T
J Neurosurg; 2007 Feb; 106(2):299-305. PubMed ID: 17410715
[TBL] [Abstract][Full Text] [Related]
13. Synergism between GM-CSF and IFNgamma: enhanced immunotherapy in mice with glioma.
Smith KE; Janelidze S; Visse E; Badn W; Salford L; Siesjö P; Darabi A
Int J Cancer; 2007 Jan; 120(1):75-80. PubMed ID: 17044023
[TBL] [Abstract][Full Text] [Related]
14. Glioma immunotherapy with combined autologous tumor cell and endothelial cell vaccine in vivo.
Sakamoto N; Uemae Y; Ishikawa E; Takano S; Nakai K; Yamamoto T; Zaboronok A; Matsumura A
Neurol Med Chir (Tokyo); 2012; 52(4):194-201. PubMed ID: 22522329
[TBL] [Abstract][Full Text] [Related]
15. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity.
Verschuere T; Toelen J; Maes W; Poirier F; Boon L; Tousseyn T; Mathivet T; Gerhardt H; Mathieu V; Kiss R; Lefranc F; Van Gool SW; De Vleeschouwer S
Int J Cancer; 2014 Feb; 134(4):873-84. PubMed ID: 23929302
[TBL] [Abstract][Full Text] [Related]
16. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
[TBL] [Abstract][Full Text] [Related]
17. Mouse glioma immunotherapy mediated by A2B5+ GL261 cell lysate-pulsed dendritic cells.
Xu M; Yao Y; Hua W; Wu Z; Zhong P; Mao Y; Zhou L; Luo F; Chu Y
J Neurooncol; 2014 Feb; 116(3):497-504. PubMed ID: 24398615
[TBL] [Abstract][Full Text] [Related]
18. Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas.
Abdelwahab MG; Sankar T; Preul MC; Scheck AC
J Vis Exp; 2011 Nov; (57):e3403. PubMed ID: 22158303
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effects of a xenogeneic survivin bone marrow derived dendritic cell vaccine against murine GL261 gliomas.
Ciesielski MJ; Apfel L; Barone TA; Castro CA; Weiss TC; Fenstermaker RA
Cancer Immunol Immunother; 2006 Dec; 55(12):1491-503. PubMed ID: 16485128
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of TLR9 with CpG ODN enhances apoptosis of glioma and prolongs the survival of mice with experimental brain tumors.
El Andaloussi A; Sonabend AM; Han Y; Lesniak MS
Glia; 2006 Nov; 54(6):526-35. PubMed ID: 16906541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
